AbbVie Expands IPF Pipeline With New Phase 2a Study of ABBV-142

Abbvie (ABBV) announced an update on their ongoing clinical study.

AbbVie (ABBV) is running a mid-stage trial to test new drugs for idiopathic pulmonary fibrosis (IPF), a chronic lung disease with limited treatment options. The official name is a Phase 2a multicenter platform study of investigational products in adults with IPF, aimed at checking safety, tolerability, and early signs that the drugs can slow or improve disease activity.

The main drug in the first part of the study, ABBV-142, is an experimental pill designed to treat IPF by targeting disease pathways that drive lung scarring. It is compared with a matching placebo to see if it can reduce symptoms and lung damage while keeping side effects manageable over a one-year treatment period.

The study is interventional and randomized, meaning patients are assigned by chance to ABBV-142 or placebo in parallel groups. It is also double-blind and uses a placebo control, so neither patients nor doctors know who gets active treatment, and the primary goal is to test ABBV-142 as a potential new therapy for IPF.

The trial began enrolling after its initial submission on 2025-11-14 and is now in the recruiting phase, reflecting active site and patient startup. The latest update was filed on 2026-02-19, signaling that AbbVie has recently refreshed protocol or operational details, but primary and final completion dates have not yet been reached.

For investors, this update underlines AbbVie’s push into rare lung disease, a niche with high unmet need and pricing power. If ABBV-142 shows solid safety and early benefit, it could support long-term revenue growth and help diversify beyond AbbVie’s existing immunology and oncology lines, which may lift sentiment around the IPF pipeline.

The IPF field already includes players such as Roche, Boehringer Ingelheim, and others with approved therapies that slow but do not stop disease. A positive data path for ABBV-142 could pressure older drugs and raise expectations that AbbVie can gain share in a market willing to adopt better options despite premium pricing.

Near term, the study is still in an early phase, so major stock moves are unlikely until interim or top-line data arrive. However, consistent trial progress updates support the narrative that AbbVie is investing in durable growth areas, which may help underpin valuation during periods of volatility in other core franchises.

This Phase 2a platform study of ABBV-142 in IPF is ongoing and recently updated, with further details available on the ClinicalTrials.gov portal.

To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.